We identified 13 out of 17 IBC tumours with EGFR and/or ErbB2 overexpression compared to only one non-IBC tumour with EGFR and/or ErbB2 overexpression (κ=0.742, P<0.0001). Here, EGFR is linked to inflammatory breast carcinoma.